Suvretta Capital Management LLC Has $3.80 Million Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Suvretta Capital Management LLC reduced its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 63.3% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 13,824 shares of the biopharmaceutical company’s stock after selling 23,800 shares during the period. Suvretta Capital Management LLC’s holdings in Alnylam Pharmaceuticals were worth $3,802,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Blueshift Asset Management LLC bought a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter valued at about $293,000. Bridgewater Associates LP bought a new position in shares of Alnylam Pharmaceuticals during the 3rd quarter worth approximately $551,000. Brooklyn Investment Group acquired a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter worth approximately $114,000. Quantbot Technologies LP increased its stake in shares of Alnylam Pharmaceuticals by 1,754.5% in the 3rd quarter. Quantbot Technologies LP now owns 204 shares of the biopharmaceutical company’s stock valued at $56,000 after acquiring an additional 193 shares in the last quarter. Finally, Harvest Fund Management Co. Ltd acquired a new position in shares of Alnylam Pharmaceuticals during the 3rd quarter valued at $45,000. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Tolga Tanguler sold 1,469 shares of the stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total transaction of $368,689.62. Following the sale, the executive vice president now owns 13,191 shares in the company, valued at $3,310,677.18. This represents a 10.02 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CMO Pushkal Garg sold 1,682 shares of the firm’s stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total value of $422,148.36. Following the completion of the transaction, the chief marketing officer now directly owns 17,457 shares of the company’s stock, valued at $4,381,357.86. The trade was a 8.79 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 8,370 shares of company stock worth $2,100,703. Company insiders own 1.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $400.00 price target on shares of Alnylam Pharmaceuticals in a research note on Monday, November 18th. Scotiabank boosted their target price on Alnylam Pharmaceuticals from $305.00 to $310.00 and gave the company a “sector outperform” rating in a research report on Friday, November 1st. Bank of America increased their price target on Alnylam Pharmaceuticals from $307.00 to $314.00 and gave the stock a “buy” rating in a report on Monday, October 14th. Wells Fargo & Company upped their target price on Alnylam Pharmaceuticals from $207.00 to $233.00 and gave the stock an “equal weight” rating in a research report on Friday, August 2nd. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $300.00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday, November 1st. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and eighteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $298.09.

Alnylam Pharmaceuticals Trading Up 0.2 %

NASDAQ:ALNY opened at $253.74 on Friday. Alnylam Pharmaceuticals, Inc. has a 12 month low of $141.98 and a 12 month high of $304.39. The company has a current ratio of 2.75, a quick ratio of 2.69 and a debt-to-equity ratio of 31.64. The firm’s 50 day moving average is $271.93 and its 200 day moving average is $240.19. The stock has a market capitalization of $32.73 billion, a PE ratio of -96.85 and a beta of 0.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The business had revenue of $500.90 million during the quarter, compared to analysts’ expectations of $532.91 million. Alnylam Pharmaceuticals’s revenue for the quarter was down 33.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.15 EPS. Sell-side analysts expect that Alnylam Pharmaceuticals, Inc. will post -2.21 earnings per share for the current year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.